Literature DB >> 1689122

CSF monoamine levels in normal-weight bulimia: evidence for abnormal noradrenergic activity.

W H Kaye1, J C Ballenger, R B Lydiard, G W Stuart, M T Laraia, P O'Neil, M D Fossey, V Stevens, S Lesser, G Hsu.   

Abstract

Normal-weight bulimic patients have disturbed appetite, mood, and neuroendocrine function and often respond to antidepressants. Since these findings suggest abnormalities in brain monoaminergic pathways, the authors measured CSF monoamine concentrations in 27 normal-weight bulimic patients and 14 volunteers. Bulimic patients had a significantly lower mean CSF norepinephrine concentration. Levels of CSF 5-HIAA, the major serotonin metabolite, and CSF HVA, the major dopamine metabolite, were normal, although more frequent binge-eating in bulimic subjects was associated with a significantly lower CSF HVA level. Whether trait- or state-related, monoaminergic disturbances are part of this disorder's neurobiological syndrome. The lower CSF norepinephrine concentration suggests bulimia is not simply a variant of affective disorders.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1689122     DOI: 10.1176/ajp.147.2.225

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  19 in total

Review 1.  Psychopharmacotherapy of anorexia nervosa, bulimia nervosa and binge-eating disorder.

Authors:  S Krüger; S H Kennedy
Journal:  J Psychiatry Neurosci       Date:  2000-11       Impact factor: 6.186

2.  Baclofen, raclopride, and naltrexone differentially affect intake of fat/sucrose mixtures under limited access conditions.

Authors:  K J Wong; F H W Wojnicki; R L W Corwin
Journal:  Pharmacol Biochem Behav       Date:  2009-02-13       Impact factor: 3.533

3.  Altered temporal difference learning in bulimia nervosa.

Authors:  Guido K W Frank; Jeremy R Reynolds; Megan E Shott; Randall C O'Reilly
Journal:  Biol Psychiatry       Date:  2011-06-29       Impact factor: 13.382

Review 4.  Pharmacological manipulations in animal models of anorexia and binge eating in relation to humans.

Authors:  M A van Gestel; E Kostrzewa; R A H Adan; S K Janhunen
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

Review 5.  Aetiopathogenesis and pathophysiology of bulimia nervosa: biological bases and implications for treatment.

Authors:  F Brambilla
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 6.  Does a shared neurobiology for foods and drugs of abuse contribute to extremes of food ingestion in anorexia and bulimia nervosa?

Authors:  Walter H Kaye; Christina E Wierenga; Ursula F Bailer; Alan N Simmons; Angela Wagner; Amanda Bischoff-Grethe
Journal:  Biol Psychiatry       Date:  2013-02-04       Impact factor: 13.382

7.  Interaction between serotonin transporter and dopamine D2/D3 receptor radioligand measures is associated with harm avoidant symptoms in anorexia and bulimia nervosa.

Authors:  Ursula F Bailer; Guido K Frank; Julie C Price; Carolyn C Meltzer; Carl Becker; Chester A Mathis; Angela Wagner; Nicole C Barbarich-Marsteller; Cinnamon S Bloss; Karen Putnam; Nicholas J Schork; Anthony Gamst; Walter H Kaye
Journal:  Psychiatry Res       Date:  2012-11-13       Impact factor: 3.222

8.  Serotonin-induced decrease of intracellular Ca(2+) release in platelets of bulimic patients normalizes during treatment.

Authors:  Lars Wöckel; Florian Daniel Zepf; Sabrina Koch; Anikó-Eva Meyer-Keitel; Martin H Schmidt
Journal:  J Neural Transm (Vienna)       Date:  2008-12-10       Impact factor: 3.575

Review 9.  Eating disorders. A review and update.

Authors:  E Haller
Journal:  West J Med       Date:  1992-12

10.  Effects of chronic brofaromine administration on biogenic amines including sulphatoxymelatonin and acid metabolites in patients with bulimia nervosa.

Authors:  S H Kennedy; B A Davis; G M Brown; C G Ford; J d'Souza
Journal:  Neurochem Res       Date:  1993-12       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.